We are live on ! Find out more
CANF

Can-Fite BioPharma American Depositary Shares
CANF

14 hedge funds and large institutions have $429K invested in Can-Fite BioPharma American Depositary Shares in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital invested

Capital invested by funds: $271K → $429K (+$157K)

6.34% more ownership

Funds ownership: 0.11% → 6.45% (+6.3%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

7% less funds holding

Funds holding: 15 → 14 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

Holders
14
Holders Change
-1
Holders Change %
-6.67%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$176K
2
Citadel Advisors
Citadel Advisors
Florida
+$141K
3
HF
HRT Financial
New York
+$80.1K
4
VF
Virtu Financial
New York
+$53.4K
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$28.2K

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$193K
2
Osaic Holdings
Osaic Holdings
Arizona
-$5.58K
3
XT
XTX Topco
Cayman Islands
-$3.74K
4
BWL
Bogart Wealth LLC
Virginia
-$3.01K
5
TSS
Two Sigma Securities
New York
-$2.42K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$132K +$176K +42,559 New
Citadel Advisors
2
Citadel Advisors
Florida
$106K +$141K +34,150 New
RhumbLine Advisers
3
RhumbLine Advisers
Massachusetts
$64.8K +$28.2K +6,814 +48%
HF
4
HRT Financial
New York
$60K +$80.1K +19,383 New
VF
5
Virtu Financial
New York
$40K +$53.4K +12,908 New
Citigroup
6
Citigroup
New York
$17K +$22.7K +5,482 New
UBS Group
7
UBS Group
Switzerland
$6.67K +$4.57K +1,105 +106%
Osaic Holdings
8
Osaic Holdings
Arizona
$1.4K -$5.58K -1,350 -75%
Fifth Third Bancorp
9
Fifth Third Bancorp
Ohio
$465 – – –
Wells Fargo
10
Wells Fargo
California
$388 – – –
AWM
11
Activest Wealth Management
Florida
$31 – – –
Morgan Stanley
12
Morgan Stanley
New York
$3 -$4 -1 -50%
TWC
13
TD Waterhouse Canada
Ontario, Canada
$3 – – –
Jane Street
14
Jane Street
New York
– -$193K -10,250 Closed
XT
15
XTX Topco
Cayman Islands
– -$3.74K -934 Closed
BWL
16
Bogart Wealth LLC
Virginia
– -$3.01K -752 Closed
TSS
17
Two Sigma Securities
New York
– -$2.42K -604 Closed
CAM
18
Costello Asset Management
Pennsylvania
– -$200 -50 Closed
EWA
19
EverSource Wealth Advisors
Alabama
– -$14 -3 Closed

CANF Hedge Fund Activity: Q1 2026 in Review

14 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q1 2026, worth a combined $429K — up 58% from $271K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CANF and 5 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $176K. The largest seller was Jane Street, exiting entirely with an estimated $193K sold.

  • 14 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q1 2026, down from 15 in Q4 2025.
  • Funds reported $429K of Can-Fite BioPharma American Depositary Shares stock for Q1 2026, up 58% quarter-over-quarter.
  • 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q1 2026 and 6 closed out, a net change of -1 holder.
  • The largest Can-Fite BioPharma American Depositary Shares buyer in Q1 2026 was Sabby Management, an estimated $176K added.
  • The largest Can-Fite BioPharma American Depositary Shares seller in Q1 2026 was Jane Street, an estimated $193K sold.

Based on aggregated 13F filings for Q1 2026.